Markus Eickmann

Research interests

Publications

• Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial

  The Lancet Infectious Diseases · 2020 · 10.1016/s1473-3099(20)30248-6

• TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells

  Life Science Alliance · 2020 · https://doi.org/10.26508/lsa.202000786

• Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmc2001899

• Inactivation of three emerging viruses – severe acute respiratory syndrome coronavirus, Crimean–Congo haemorrhagic fever virus and Nipah virus – in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light

  Vox Sanguinis · 2020 · 10.1111/vox.12888

• In Vitro Bactericidal and Virucidal Efficacy of Povidone-Iodine Gargle/Mouthwash Against Respiratory and Oral Tract Pathogens

  Infectious Diseases and Therapy · 2018 · 10.1007/s40121-018-0200-7

• New Lineage of Lassa Virus, Togo, 2016

  Emerging infectious diseases · 2018 · 10.3201/eid2403.171905

• Virucidal Activity of World Health Organization–Recommended Formulations Against Enveloped Viruses, Including Zika, Ebola, and Emerging Coronaviruses

  The Journal of Infectious Diseases · 2017 · 10.1093/infdis/jix046

• Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever

  Clinical Infectious Diseases · 2017 · 10.1093/cid/cix406

• Rapid and Effective Virucidal Activity of Povidone-Iodine Products Against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Modified Vaccinia Virus Ankara (MVA)

  Infectious Diseases and Therapy · 2015 · 10.1007/s40121-015-0091-9

• Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1502924

• The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial

  The Lancet Infectious Diseases · 2015 · 10.1016/s1473-3099(15)00154-1

• Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein

  Journal of Virology · 2015 · 10.1128/jvi.00614-15

• Human Cell Tropism and Innate Immune System Interactions of Human Respiratory Coronavirus EMC Compared to Those of Severe Acute Respiratory Syndrome Coronavirus

  Journal of Virology · 2013 · https://doi.org/10.1128/jvi.03496-12

• Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics

  Science Translational Medicine · 2013 · 10.1126/scitranslmed.3006368

• Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies

  Journal of Virology · 2013 · 10.1128/jvi.01672-13

• Cleavage of Influenza Virus Hemagglutinin by Airway Proteases TMPRSS2 and HAT Differs in Subcellular Localization and Susceptibility to Protease Inhibitors

  Journal of Virology · 2010 · 10.1128/jvi.00140-10

• Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray

  Nature Biotechnology · 2009 · 10.1038/nbt0909-797

• Synthesis and Characterization of a Native, Oligomeric Form of Recombinant Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein

  Journal of Virology · 2004 · https://doi.org/10.1128/jvi.78.19.10328-10335.2004

• Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome

  New England Journal of Medicine · 2003 · https://doi.org/10.1056/nejmoa030747

• Identification of Lassa virus glycoprotein signal peptide as a trans‐acting maturation factor

  EMBO Reports · 2003 · 10.1038/sj.embor.7400002

• SARS — beginning to understand a new virus

  Nature Reviews Microbiology · 2003 · https://doi.org/10.1038/nrmicro775

Current projects

No projects listed.